The M. D. Anderson Myeloma SPORE Career Development Program (CDP) has the following objectives: 1. Recruit and train physicians, scientists, and senior postdoctoral fellows to become outstanding translational investigators in myeloma research. 2. Establish a Structure for Project Identification and Selection. Publicize the availability of start-up funding for pilot projects in myeloma translational research. Develop a peer-review mechanism to select competing proposals for funding using internal and external reviewers. Develop specific criteria for selection of projects for funding for use by the reviewers. The SPORE Administrative Core plays a major role in this. Identify projects that are innovative and have significant potential for improving treatment outcome of myeloma. The expertise of SPORE Pis, Project Leaders, Co-Investigators, and the scientific advisory board will be sought to achieve this goal. 3. Provide funding, resources, and encourage SPORE Collaborations. Provide development funding (usually in the amount of-$50,000) for projects in the M. D. Anderson Myeloma SPORE and for scientists at other institutions outside the SPORE environment. Encourage collaborations among scientists in the SPORE and with scientists outside the SPORE environment that will help investigators reach their objectives. Connect young investigators with other myeloma basic and clinical investigators at M. D. Anderson and at other SPORE institutions. The SPORE PI and Co-PI will work with investigators to define translational research goals and steps required to effectively and rapidly translate the research into application in humans. The CDP will facilitate access to SPORE Cores needed to reach these goals - Myeloma Tissue, Clinical Trials, Animal Models, Bioinformatics and Biostatistics, and GMP laboratory Cores. 4. Provide Mentorship for Career Development Awardees. Develop a mechanism for closely mentoring and monitoring the work ofthe Career Development Awardees to help achieve their translational research goals. Require Career Developmental Project investigators to give official presentations of their work at the regular monthly SPORE meetings as well as annual written reports. Provide expert mentors in myeloma translational research for the Career Development Projects. Review and help Career Development Project Investigators prepare their results for presentation and encourage presentation at inter-SPORE meetings, such as at the annual SPORE meeting. 5. Provide Assistance and Guidance For Obtaining Independent Peer Reviewed Funding. Require, with assistance, preparation of other peer-reviewed funding applications, such as R21 and Foundation grants, and help with grant draft review, and provide letters of support for these applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-05
Application #
8728784
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
$90,256
Indirect Cost
$4,919
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239
Thomas, Sheeba K; Cha, Soung-Chul; Smith, D Lynne et al. (2018) Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18:187
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397
Davenport, Clemontina A; Maity, Arnab; Baladandayuthapani, Veerabhadran (2018) Functional interaction-based nonlinear models with application to multiplatform genomics data. Stat Med 37:2715-2733
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Hao, Suyang; Lin, Pei; Medeiros, L Jeffrey et al. (2017) Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30:1378-1386
Purushothaman, Anurag; Bandari, Shyam K; Chandrashekar, Darshan S et al. (2017) Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget 8:73723-73732

Showing the most recent 10 out of 203 publications